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Abstract  
Background 
Haemostasis in liver surgery remains a challenge despite improved resection techniques. 
Oozing from blood vessels too small to be ligated necessitate a treatment with 
haemostats in order to prevent complications attributed to bleeding. There is good 
evidence from randomised trials for the efficacy of fibrin sealants, on their own or in 
combination with a carrier material. A new haemostatic device is Sangustop
®. It is a 
collagen based material without any coagulation factors. Pre-clinical data for 
Sangustop
® showed superior haemostatic effect. This present study aims to show that in 
the clinical situation Sangustop
® is not inferior to a carrier-bound fibrin sealant 
(Tachosil
®) as a haemostatic treatment in hepatic resection. 
 
Methods/Design 
This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A 
total of 126 patients planned for an elective liver resection will be enrolled in eight 
surgical centres. The primary objective of this study is to show the non-inferiority of 
Sangustop® versus a carrier-bound fibrin sealant (Tachosil®) in achieving haemostasis 
after hepatic resection. The surgical intervention is standardised with regard to devices 
and techniques used for resection and primary haemostasis. Patients will be followed-up 
for three months for complications and adverse events. 
 
Discussion 
This randomised controlled trial (ESSCALIVER) aims to compare the new collagen 
haemostat Sangustop
® with a carrier-bound fibrin sealant which can be seen as a ”gold - 3 - 
standard” in hepatic and other visceral organ surgery. If non-inferiority is shown other 
criteria than the haemostatic efficacy (e.g. costs, adverse events rate) may be considered 
for the choice of the most appropriate treatment. 
 
Trial Registration: NCT00918619   - 4 - 
Background 
All  surgical  procedures  inevitably  lead  to  bleeding.  Haemostasis  –  the  control  of 
bleeding - aims at reducing the amount of blood loss and the need for transfusion as 
well as preventing re-bleeding, haematoma formation with subsequent morbidities, and 
the  need  for  intervention  or  repeat  surgery.  During  liver  resection  the  control  of 
bleeding is a major concern. The liver is predisposed to a diffuse bleeding because of its 
extreme vascularity, particularly because of the hepatic sinusoidal structure, which does 
not have smooth muscles capable of contraction to induce vasoconstriction.  
 
Surgical techniques and devices to facilitate haemostasis have been developed in the last 
decades  and  have  minimised  operative  risks  of  liver  resection.  Nevertheless,  a 
parenchymal transsection of the liver tissue is always associated with some degree of 
bleeding  due  to  the  division  of  small  blood  vessels  which  can  not  be  isolated  and 
ligated.  
 
In order to achieve control over that parenchymatic diffuse bleeding from the resection 
surface  and  to  prevent  intraperitoneal  complications  attributed  to  bleeding  various 
locally applicable agents (haemostats) are in use. These haemostats include bone wax, 
gelatine,  collagen,  oxidized  regenerated  cellulose,  fibrin  sealant  glues,  and  synthetic 
glues [1]. Some evidence from randomized controlled trials (RCT) exists regarding the 
use of fibrin sealants on their own or combined with a collagen fleece [2,3].  
 
A  composite  product  with  well  documented  efficacy  is  Tachosil
®  [Nycomed,  Linz, 
Austria]. It consists of a collagen fleece carrying the fibrin glue components human 
fibrinogen and human thrombin. It was shown in a RCT to be superior in obtaining - 5 - 
intraoperative  haemostasis  over  argon  beamer  in  liver  resection  [4].  The  time  to 
haemostasis was significantly reduced. Also in kidney tumour resection a randomized 
study showed superiority over standard suturing [5]. 
 
A  new  haemostat  product  is  Sangustop
®  [Aesculap,  Tuttlingen,  Germany].  It  is 
indicated  for  local  haemostasis  of  capillary  bleeding  and  bleeding  of  parenchymal 
organs. Sangustop
® is composed of native absorbable collagen fibrils without any blood 
serum products or any pharmaceutical activity. The felt structure being rich in surface 
gives  a  framework  for  the  adhesion  of  blood  platelets,  thus  provides  an  additional 
impetus to clotting. Pre-clinical data showed very good haemostatic activity, superior to 
sealant and to cellulose product [6]. 
 
The  aim  of  this  study  is  to  show  that  the  new  microfibrillar  collagen  hemostat 
Sangustop
® is not inferior to the carrier-bound fibrin sealant Tachosil
® with regards to 
haemostatic efficacy. The efficacy of Tachosil
® has been shown in many clinical studies 
in various indications and thus can be seen as a standard treatment superior to other 
locally applicable agents [4, 5].  
 
Methods/Design  
Objectives 
This study is designed as a prospective, single blinded, randomized, 2-arm trial of two 
haemostatic products. The primary objective of the study is to show the non-inferiority 
of Sangustop
® (Treatment Arm 1) versus Tachosil
® (Treatment Arm 2) in achieving 
haemostasis after hepatic resection.  
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Primary endpoint 
￿ Haemostasis 3 minutes after application of the haemostatic product. 
 
Secondary endpoints 
￿ Haemostasis 5 minutes after application of the haemostat product. 
￿ Haemostasis 10 minutes after application of the haemostat product.  
￿ Time to haemostasis 
￿ Complications and adverse events intra-operatively during liver resection and during 
3 months of follow-up. 
 
Interventions 
Surgery 
Liver resection (segmental or non-segmental) will be performed according to accepted 
surgical standards. Surgeons must be board certified and must have a minimum 
experience of 10 liver resections performed. A standardization of surgical technique will 
be done inasmuch as there is a restriction in the methods allowed for resection and for 
primary haemostasis.  
  
The following techniques of liver resection are allowed:  
￿ Cavitron Ultrasonic Aspiration (CUSA
®) 
￿ Hydrojet (pressurized jet of water) 
￿ Clamp Crushing  
￿ Scissors 
￿ Stapler transsection  
 - 7 - 
The following techniques of liver resection are not permitted: 
￿ Argon beamer (Argon-Plasma Coagulation) 
￿ Radiofrequency-assisted devices for parenchymal division (e.g. Habib™-Sealer, 
TissueLink™) 
￿ Ultrasonic dissection (e.g. UltraCision
®) 
 
The following methods of primary haemostasis are allowed: 
￿ Vascular clips 
￿ Sutures 
All other methods of primary haemostasis (e.g. Argon Laser, bipolar coagulation) are 
not permitted. 
 
After primary haemostasis has been achieved and with persistent parenchymal bleeding 
the patient will be randomized to one of two treatment groups. Either Sangustop
® or 
Tachosil
®  will be applied to the resection area according to the respective instructions 
for use and the time to haemostasis will be recorded. 
 
 
Follow-up 
After surgery, two follow-up examinations will be performed while the patients are still 
hospitalised. Patients are observed for 3 months for documentation of adverse events. 
See Table 1 for detailed follow-up. 
 
Study materials - 8 - 
Sangustop
® (B. Braun Aesculap, Tuttlingen, Germany) is a felt-like haemostatic agent, 
composed of native absorbable collagen fibrils of bovine origin and containing 
riboflavin as a colouring agent.  
TachoSil® (Nycomed, Linz, Austria) is a ready-to-use fixed combination of a patch 
sponge (equine collagen) coated with a dry layer of the human coagulation factors 
fibrinogen and thrombin.  
Both investigational products of this clinical trial are approved for clinical use (CE-
mark and EU Marketing Authorisation, respectively). They will be used according to 
respective instructions for use within their usual range of indication.  
 
Trial population 
Clinical trial participants will be recruited in the clinical trial centres consecutively from 
a population of patients who are planned for an elective liver resection. A detailed 
overview of the eligibility criteria is given in Table 2. One part of the eligibility criteria 
are checked preoperatively. A second set of criteria must be checked intra operatively. 
Patients who do not meet the second part of the eligibility criteria will neither be 
randomised nor treated with an investigational product. Their trial participation will end 
by this time. Regular monitoring visits will be performed and the eligibility of all 
enrolled patients will be checked by source data verification. Resection area will be 
calculated with the aid of a paper blot of the resection surface. 
 
Sample size 
The sample size was calculated to test for non-inferiority of Treatment Arm 1 
(Sangustop® ) versus Treatment Arm 2 (Tachosil® ) in terms of haemostasis 3 minutes 
after application of the haemostatic product. The proportion of patients with a complete - 9 - 
haemostasis 3 minutes after application will be assessed. In a previous study [4] the 
proportion of patients with complete blood clotting after 3 minutes for Tachosil® was 
estimated to be 73%. 
 
With 60 subjects in each group, the lower limit of the observed one-sided 97,5% 
confidence interval will be expected to exceed -0,100 with 93% power when the 
proportion of Treatment Arm 2, πS, is 0,730 and the expected proportion of Treatment 
Arm 1, πT, is 0,880; results are based on 100 simulations using the Newcombe-Wilson 
score method to construct the confidence interval [7].  
 
In case of non-inferiority an additional two group χ
2-test with a 0,050 two-sided 
significance level will have 83% power to detect the difference between an Treatment 
Arm 2 proportion, π1, of 0,730 and an Treatment Arm 1 proportion, π2, of 0,930 (odds 
ratio of 4,914) when the sample size in each group is 60. 
 
Assuming a drop-out rate of 5% a total number of 126 patients needs to be enrolled. 
Figure 1 shows a flow diagram of the progress through the trial phases.  
 
 
Randomisation and blinding 
Randomisation is designed in a way that both treatment arms will have the same number 
of patients, with a randomisation ratio of 1:1 providing equal probability of assignment
  
to each of the two treatment arms. Randomisation is stratified by clinical trial centre and 
will be performed as block randomization. A separate randomisation list will be created - 10 - 
for  each  clinical  trial  centre  using  the  Software  RandList  of  the  DatInf  GmbH, 
Tübingen, Germany.   
 
Only  if  a  patient  fulfils  all  eligibility  criteria  he/she  will  be  randomised  to  an 
investigational treatment. This will take place during surgery, since part of the exclusion 
criteria can only be checked during the operation (liver resection). For allocation of the 
randomisation numbers  to eligible trial participants each clinical trial  centre will be 
provided with a set of identical look, opaque and well sealed envelopes. If a patient 
turns out to be eligible the investigator opens the next envelope in sequence. Inside he 
will  find  the  randomisation  number  and  the  allocated  investigational  treatment.  The 
sequence of opening the envelopes will be monitored regularly. 
 
This is a single blinded clinical trial. The clinical trial patients will not be informed 
about their assignment to a study group. The randomization takes place in the operating 
room immediately before the application of the product. Thus the investigator does not 
know which product will be used during transection, during primary haemostasis, and 
when assessing the intra-operative inclusion criteria. However, the appearance of the 
products precludes a complete blinding of the investigators. 
 
 
Statistical analysis 
Primary Variable 
The proportion of patients with haemostasis 3 minutes after application of the haemostat 
product as well as associated 95% confidence intervals will be reported for each 
treatment arm. The study null hypothesis is that Tachosil®  is more effective than - 11 - 
Sangustop®. Non-inferiority will be demonstrated if the lower limit of the observed 
two-sided 95% confidence interval of the observed difference in proportions of 
Treatment Arm 1 – Treatment Arm 2 does not fall below –0.100. The analysis will be 
based on the per-protocol population and repeated for the intent-to-treat population. The 
intent-to-treat population consists of all consenting patients randomized into the study. 
The safety population comprises all treated patients. The Per-Protocol population 
excludes all patients who violated inclusion or exclusion criteria of the protocol. 
If the 95% confidence interval for the treatment effect not only lies entirely above –0.1 
but also above zero then there is evidence of superiority in terms of statistical 
significance at the 5% level. The difference in proportions between the two treatment 
arms (Treatment Arm 1 versus Treatment Arm 2) will be tested with a Fisher’s exact 
test to reject the null hypothesis of no difference.  
 
Secondary Variables 
The proportion of patients with haemostasis 5 minutes and 10 minutes after application 
will be reported descriptively based on intent-to-treat population as well as the per-
protocol population. This will include the proportions, the estimated difference in 
proportions and the associated 95% confidence intervals. Differences in time to 
haemostasis will be tested with a log-rank test at the 5% alpha level. Kaplan Meier 
curves will be displayed, with median estimates and confidence limits provided. The 
analyses will be based on the intent-to-treat population and repeated for the per-protocol 
population. 
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Trial organization 
The trial is initiated and sponsored by B. Braun Aesculap. The sponsors role during 
study conduct is limited to the project co-ordination. An external Clinical Research 
Organisation (Centrial GmbH, Tübingen, Germany) is engaged for monitoring, 
biometry, and data management.  
 
Patients will be recruited by seven German and one Austrian hospitals. Sites are 
selected according their experience in liver surgery and their willingness to adhere to 
the study protocol. The participating centres are listed at the end of this paper. 
 
The trial is performed according to the Declaration of Helsinki in its current German 
version, the national laws for medical devices and for drugs, and the guidelines for 
Good Clinical Practice (GCP), as applicable. The study was approved by the ethics 
committee of the Johann Wolfgang Goethe-University, Department of Medicine, 
Frankfurt, Germay; approval number 197/09. 
 
 
Data management and quality assurance 
Data is entered in prepared Clinical Report Forms (CRF). Completed CRF pages are 
checked by the responsible monitor with respect to completeness and plausibility. The 
data will be transferred into an electronic data processing system by the CRO (CenTrial 
GmbH). A double data entry will be performed with a double data check. During the 
recruitment phase the centres will be monitored according to GCP guidelines by 
qualified monitors from the CRO. 
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Ethical aspects 
The study was approved by the Ethics Committee of the University of Frankfurt. 
Secondary approvals will be obtained from all ethics committees responsible for the 
participating centres. Written informed consent will be obtained from all study subjects 
before enrolment into the study. 
 
Current status and duration of the trial 
The study protocol has been completed in January 2009. A first investigator meeting 
was held in April, 2008, where the key points of the study design were discussed and 
agreed on by all clinical trial centres. Patient recruitment started in January, 2010 and is 
planned to require 12 months. At the time of submission recruitment is active in six of 
the eight participating centres. 
 
Discussion 
 
Postoperative  bleeding  and  biliary  leakage  are  -  despite  advancement  in  resection 
technique – major determinants of morbidity after liver resection, encountered in 4% to 
7% of patients [8]. Topical haemostats, glues and sealants are used regularly in liver 
surgery  trying  to  prevent  complications  resulting  from  haemorrhage.  The  ideal 
haemostat should be efficient in achieving fast and durable haemostasis and not causing 
any adverse affects. Additionally, it should be easy to use and cost efficient.  
 
The present study aims to show that the efficacy of a new collagen based haemostyptic 
agent (Sangustop®) is not inferior to another product with a proven efficacy 
(Tachosil®). A non-inferiority study design seems to be appropriate, since there is good - 14 - 
evidence from controlled trials that the active control is efficacious. The expected 
margins of a possible difference are so small – in the range of seconds or few minutes 
regarding time to haemostasis - that the clinical relevance of a superiority would be at 
least questionable. In case Sangustop® proves to be no worse than Tachosil®, other 
criteria like incompatibility with the use of human blood components or cost-
effectiveness could be taken into consideration. With haemostats potentially being used 
in all surgical procedures and with the relatively high costs of fibrin sealants and similar 
products, the cost-effectiveness is of a high importance. The results of this study could 
influence the choice of haemostatic therapy in a great many cases, especially with 
extensive parenchymatic bleeding, such as in hepatic resections. 
 
Purified, microfibrillar  collagen products have been introduced as haemostats in the 
1970ies  and  have  become  valuable  surgical  adjunctives.  They  induce  blood  clotting 
very  fast,  have  a  strong  adherence  to  the  surface  with  low  tissue  reaction  and  fast 
resorption [9]. Preclinical data on the new collagen product Sangustop
® showed very 
good  haemostatic  activity.  In  a  pig  liver  resection  model  time  to  haemostasis  was 
shorter than for Tachosil
® or for oxidized cellulose [6]. 
 
Some evidence from randomized controlled trials (RCT) exists regarding the use of 
fibrin sealants on their own or combined with a carrier material [2]. The efficacy of 
Tachosil®  which  consists  of  a  collagen  fleece  carrying  the  fibrin  glue  components 
human  fibrinogen  and  human  thrombin  has  been  shown  in  many  clinical  studies  in 
various indications and can be seen as a standard treatment superior to other locally 
applicable agents [4,5]. It was shown in a randomised controlled trial to be superior in 
obtaining intra-operative haemostasis over argon beamer in liver resection [4][10]. The 
study by Frilling et al. will serve as the reference for this study design and conduct. - 15 - 
Participants, interventions and outcome measures are chosen to be similar or equivalent. 
Three  study  centres  of  the  ESSCALIVER  –  Study  (Graz,  Heidelberg,  München 
Grosshadern) participated in the reference study, too. 
 
Patients undergoing elective hepatic resection are generally eligible for the study. Liver 
surgery  is  to  be  performed  according  to  accepted  surgical  standards.  For  primary 
surgical haemostasis only sutures and clips are allowed.  
 
The  efficacy  parameter  is  “time  to  haemostasis” which  is  assessed  every  minute  as 
presence  or  absence  of  haemostasis.  Different  from  the  reference  study  the  primary 
outcome measure is the proportion of patients who achieved haemostasis at 3 minutes. 
The  reference  study  for  Tachosil®  as  well  as  the  pre-clinical  data  for  Sangustop® 
suggest that at 3 minutes in the majority of cases (>70%) haemostasis will be achieved 
already. Thus the interesting “time to haemostasis” is the time between 1 and 3 minutes. 
However, the instructions for use for Tachosil® require to press the device for at least 3 
minutes to the wound surface, preventing a measurement before that time. Therefore, 
the  proportion  of  patients  with  haemostasis  after  3  minutes  was  chosen  as  the 
appropriate primary outcome. Patient proportions at other time points and the time to 
haemostasis (Kaplan Meier curves) will be assessed as secondary parameters. 
 
A limitation of the study is that due to the nature of the products a blinding of the 
observer is not possible.  Additionally,  the assessment of the time to haemostasis is 
subjective and prone to bias. However, there is no better method available. This is 
reflected by the fact that it is the method of choice in comparable studies [2, 3, 4, 5, 6, 
10].” 
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The margins of non-inferiority are a crucial decision in a non-inferiority trial [11]. The 
basis for the margin definition in this study were: the reference study, the preclinical 
data, and expert opinions. Preclinical data suggest that Sangustop®  is more efficient in 
achieving haemostasis than Tachosil®. The reference study shows that at 3 minutes in 
~70% of patients haemostasis was achieved in contrast to ~50% (difference of ~20%) 
with the comparator Argon Laser (figures are estimates from the published graphs). In 
the present study the margins for non-inferiority are set to 10% which firstly is much 
smaller than the effect of Tachosil® found in the reference study, and secondly was 
decided by the experts in a study meeting with all participating centres. 
 
Since the comparator is a pharmaceutical product the study has to be conducted under 
the strict regulations of the national drug law. On the other hand it will additionally 
assure a high quality study conduct which is a criterion for the acceptance of a non-
inferiority study results [11]. 
 
Diffuse bleeding from resection surfaces of parenchymatous organs remain a challenge 
in visceral surgery. Pre-clinical data suggest that Sangustop®  might be a very efficient 
haemostat, however, without any pharmaceutically active plasma components. The 
present study aims to assess if Sangustop® is non-inferior to the “gold-standard” 
product Tachosil®. In case Sangustop
® proves to be as efficient as Tachosil
®, this will 
allow surgeons to look at additional criteria like handling characteristics or the cost-
effectiveness for the selection of the most appropriate treatment for hemostasis.  
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Figure1: Flow-Chart acc. to CONSORT T
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Table 2: Eligibility Criteria 
 
Inclusion Criteria  Exclusion Criteria 
 
￿  Age: > 18 years 
￿  Patients with an indication for liver resection 
(segmental or non-segmental)  
￿  Willing and able to complete the clinical trial 
procedures, as described in the protocol 
￿  Signed written informed consent to 
participate in this clinical trial 
 
 
Criteria to be checked at screening visit: 
￿  Presence or sequelae of coagulation 
disorder, liver cirrhosis, Klatskin tumour 
￿  Concurrent participation in another clinical 
trial with a medical device or medicinal 
product or with interfering endpoints 
￿  Concurrent or previous therapy with 
systemic pharmacologic agents promoting 
blood clotting including but not limited to 
tranexamix acid, activated factor VII, and 
aprotinine 
￿  Known allergy or hypersensitivity to a 
component of the investigational  treatments 
Sangustop® or Tachosil®, to riboflavin or to 
proteins of bovine origin 
￿  Pregnancy or breast feeding  
￿  Inability to understand the nature and the 
extent of the trial and the procedures 
required 
 
 
Criteria to be checked during surgery : 
￿  Resection area estimated by operating 
surgeon < 16cm
2 
￿  Infected wound area 
￿  Persistent major bleeding after primary 
haemostasis  
￿  No bleeding after resection 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility  (n= 160) 
To be lost to follow-up  (n= 3) 
Sangustop
® Group  (n= 63) 
To be randomized  (n= 126) 
Liver resection  (n= 140) 
Tachosil
®Group  (n= 63) 
To be lost to follow-up  (n= 3) 
To be analyzed  (n=60 )  To be analyzed  (n=60 ) 
Figure 1